» Articles » PMID: 38890636

Engineering Nanoparticles-enabled Tumor-associated Macrophages Repolarization and Phagocytosis Restoration for Enhanced Cancer Immunotherapy

Overview
Publisher Biomed Central
Specialty Biotechnology
Date 2024 Jun 18
PMID 38890636
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-associated macrophages (TAMs) are pivotal within the immunosuppressive tumor microenvironment (TME), and recently, have attracted intensive attention for cancer treatment. However, concurrently to promote TAMs repolarization and phagocytosis of cancer cells remains challenging. Here, a TAMs-targeted albumin nanoparticles-based delivery system (M@SINPs) was constructed for the co-delivery of photosensitizer IR820 and SHP2 inhibitor SHP099 to potentiate macrophage-mediated cancer immunotherapy. M@SINPs under laser irradiation can generate the intracellular reactive oxygen species (ROS) and facilitate M2-TAMs to an M1 phenotype. Meanwhile, inhibition of SHP2 could block the CD47-SIRPa pathway to restore M1 macrophage phagocytic activity. M@SINPs-mediated TAMs remodeling resulted in the immunostimulatory TME by repolarizing TAMs to an M1 phenotype, restoring its phagocytic function and facilitating intratumoral CTLs infiltration, which significantly inhibited tumor growth. Furthermore, M@SINPs in combination with anti-PD-1 antibody could also improve the treatment outcomes of PD-1 blockade and exert the synergistic anticancer effects. Thus, the macrophage repolarization/phagocytosis restoration combination through M@SINPs holds promise as a strategy to concurrently remodel TAMs in TME for improving the antitumor efficiency of immune checkpoint block and conventional therapy.

Citing Articles

Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy.

Kuhl G, Tangney M Cancers (Basel). 2025; 17(5).

PMID: 40075571 PMC: 11899205. DOI: 10.3390/cancers17050723.


Comment on "Role of CD47 Gene Expression in Colorectal Cancer: A Comprehensive Molecular Profiling Study".

Chongjie Z, Jianjiong L J Immunother Cancer. 2025; 13(2).

PMID: 39933838 PMC: 11815398. DOI: 10.1136/jitc-2024-011008.


Immunosenescence, Physical Exercise, and their Implications in Tumor Immunity and Immunotherapy.

Yu X, Pei W, Li B, Sun S, Li W, Wu Q Int J Biol Sci. 2025; 21(3):910-939.

PMID: 39897036 PMC: 11781184. DOI: 10.7150/ijbs.100948.


Nanotherapeutics for Macrophage Network Modulation in Tumor Microenvironments: Targets and Tools.

Li R, Huang J, Wei Y, Wang Y, Lu C, Liu J Int J Nanomedicine. 2024; 19:13615-13651.

PMID: 39717515 PMC: 11665441. DOI: 10.2147/IJN.S491573.

References
1.
Wang Y, Mohseni M, Grauel A, Estrada Diez J, Guan W, Liang S . SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms. Sci Rep. 2021; 11(1):1399. PMC: 7809281. DOI: 10.1038/s41598-021-80999-x. View

2.
Zhao C, Pang X, Yang Z, Wang S, Deng H, Chen X . Nanomaterials targeting tumor associated macrophages for cancer immunotherapy. J Control Release. 2021; 341:272-284. DOI: 10.1016/j.jconrel.2021.11.028. View

3.
Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P . Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017; 14(7):399-416. PMC: 5480600. DOI: 10.1038/nrclinonc.2016.217. View

4.
Takimoto C, Chao M, Gibbs C, McCamish M, Liu J, Chen J . The Macrophage 'Do not eat me' signal, CD47, is a clinically validated cancer immunotherapy target. Ann Oncol. 2019; 30(3):486-489. DOI: 10.1093/annonc/mdz006. View

5.
Qiu N, Wang G, Wang J, Zhou Q, Guo M, Wang Y . Tumor-Associated Macrophage and Tumor-Cell Dually Transfecting Polyplexes for Efficient Interleukin-12 Cancer Gene Therapy. Adv Mater. 2020; 33(2):e2006189. DOI: 10.1002/adma.202006189. View